Skip to main content
. 2021 Sep 9;27:105. doi: 10.1186/s10020-021-00356-6

Fig. 2.

Fig. 2

Visualization of the predicted interactions between atorvastatin, raloxifene and trifluoperazine, and the SARS-CoV-2 Mpro (left panel) and RdRp (right panel)